Table 1.
Clinicopathological characteristics of the 'explorative' cohort of patients affected by Hodgkin Lymphoma and showing either a favourable ('NR', not relapsing; nr=8) or an unfavourable ('R', relapsing; nr=8) response after treatment with the LH-2004 clinical trial 4.
| Characteristic | Classification | Explorative cohort | Validation cohort | |||
|---|---|---|---|---|---|---|
| NR(d) | R(d) | NR(d) | R(d) | |||
| Sex | ||||||
| Male | 4 | 5 | 2 | 7 | ||
| Female | 4 | 3 | 4 | 0 | ||
| Age (mean) | 14,1 | 13,6 | 14 | 14,4 | ||
| Histology(a) | ||||||
| Nodular sclerosis | 7 | 5 | 2 | 4 | ||
| Mixed cellularity | 0 | 1 | 2 | 2 | ||
| Not classified | 1 | 2 | 2 | 1 | ||
| Stage(b) | ||||||
| 4 | 4 | 3 | 1 | 3 | ||
| 3 | 1 | 1 | 3 | 1 | ||
| 2 | 3 | 4 | 2 | 3 | ||
| Symptoms(c) | ||||||
| A | 4 | 6 | 1 | 4 | ||
| B | 4 | 2 | 5 | 3 | ||
Pathological and guidelines criteria to assess the relapse were drafted and discussed by AIEOP Organization 4.
(a)histology according to 42; (b)stage according to 43; (c)A, absence of systemic symptoms; B, presence of systemic symptoms, according to 43; (d)NR, absence of HL relapse within 3 years; R, relapsed HL within 3 years.